Skip to main content
ISTH 2023 Main banner
Back

    Raza Alikhan, MD FRCP FRCPath

    Consultant Haematologist & Honorary Professor
    Cardiff and Vale University Health board
    Cardiff, Wales, United Kingdom

    Dr Raza Alikhan MD FRCP FRCPath Consultant Haematologist, Haemophilai and Thrombosis Centre, University Hospital of Wales

    Chair of the British Society for Haematology (BSH) Cancer Associated Thrombosis Guideline Writing Group and member of the BSH Thrombosis and Haemostasis Task Force and Guideline Committee. UK Chief Investigator for the apixaban treatment of cancer associated thrombosis study (CARAVAGGIO) and the phase III abelacimab versus apixaban in the treatment of cancer associated VTE (ASTER) and abelacimab versus dalteparin in the treatment of gastrointestinal / genitourinary cancer associated VTE (MAGNOLIA) studies.

    Fellow of both the Royal College of Pathologists and Royal College of Physicians having received his medical degree from the University of London and completed postgraduate studies in London and Oxford. He defended his doctoral thesis on venous thromboembolism and prophylaxis in medical patients and was the UK National Lead Investigator for the rivaroxaban medical thromboprophylaxis study (MARINER).

    Dr Alikhan has been involved in phase II–IV anticoagulant clinical trials since the late 90s. His current research interests include anticoagulation in patients with cancer, the identification of risk factors and outcomes associated with anticoagulation related bleeding and the role of antidotes. He was the UK Chief Investigator for the andexanet alfa DOAC and LMWH antidote study (ANNEXA-4) and is a member of the international steering committee for the new universal anticoagulant antidote Ciraparantag.

    He has authored more than a hundred conference abstracts, peer-reviewed papers and book chapters on thrombosis and haemostasis.

    Presentation(s):